<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> initiates an <z:mp ids='MP_0001845'>inflammatory response</z:mp> in the brain that is associated with the induction of a variety of cytokines, including <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) and interleukin-1alpha/beta (IL-1alpha/beta) that contributes to <z:hpo ids='HP_0001297'>stroke</z:hpo> injury </plain></SENT>
<SENT sid="1" pm="."><plain>Transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO) in spontaneously hypertensive rat (SHR) resulted in significant increases in TNF-alpha and IL-1beta levels </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously demonstrated up-regulation of secretory phospholipase A2 IIA (sPLA2 IIA) <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression, increased PLA2 activity, and loss of <z:chebi fb="0" ids="49183">phosphatidylcholine</z:chebi> after 1-h tMCAO and 24-h reperfusion in SHR </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with TNF-alpha antibody or IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> significantly attenuated infarction volume, sPLA2 IIA protein expression, PLA2 activity and significantly restored <z:chebi fb="0" ids="49183">phosphatidylcholine</z:chebi> levels after tMCAO </plain></SENT>
<SENT sid="4" pm="."><plain>This suggests that cytokine induction up-regulates sPLA2 IIA protein expression, resulting in altered <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism that contributes to <z:hpo ids='HP_0001297'>stroke</z:hpo> injury </plain></SENT>
</text></document>